Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and Nefiracetam — mechanism, dosing, side effects, legal status, and pricing.
Alpha-GPC is a non-peptide choline-containing phospholipid derivative that serves as an acetylcholine precursor. It is not FDA-approved in the United States, where it is sold as an unregulated dietary supplement and nootropic ingredient. The compound is marketed as a prescription drug in some countries (e.g., Italy as Gliatilin) for cognitive and vascular disorders, though current regulatory approval status has not been confirmed against primary agency databases. Alpha-GPC is not identified as a WADA-prohibited substance in secondary sources.
Nefiracetam is a non-peptide small molecule in the racetam (pyrrolidinone/2-oxopyrrolidine acetamide) class, investigated as a cognitive enhancer. It was never approved by the FDA, EMA, or Japan's PMDA; Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002 after a repeat Phase III trial in dementia failed to demonstrate efficacy. A US/Canada Phase II trial in poststroke depression (600 mg and 900 mg/day) showed no overall separation from placebo, though a subgroup analysis suggested benefit in the most severely depressed patients at 900 mg. No validated therapeutic dose or approved indication exists; it is sold by research-chemical and laboratory-reagent suppliers for research use only.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
Nefiracetam
Category
Legal Status
Mechanism
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
Nefiracetam
No pricing data yet.
Check Nefiracetam prices →COA corpus from Disclosed Labs — independently tested batches only.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
No COA data yet.
Submit testing data →Nefiracetam
2
COAs
99.6%
Avg purity
2
Labs
Human data: A 12-week randomized controlled trial in 100 subjects with amnestic mild cognitive impairment found 600 mg/day improved ADAS-cog scores by 2.34 points versus placebo with no serious adverse events. A single-blind RCT in 39 healthy volunteers showed 400 mg/day for 2 weeks increased self-reported motivation versus placebo. A small crossover study in 7 resistance-trained men (published only as a conference-supplement abstract) reported a single acute 600 mg dose increased post-exercise growth hormone and peak bench-press force versus placebo. A large retrospective Korean cohort study (n=12,008,977 adults ≥50) found chronic alpha-GPC use associated with elevated 10-year stroke risk (total stroke adjusted HR 1.43, ischemic stroke aHR 1.34) in a dose-dependent pattern. Preclinical: Rat studies showed increased hippocampal acetylcholine release, modulation of choline acetyltransferase/acetylcholinesterase activity in aged rats, attenuation of age-related brain structural changes, and increased hippocampal neurogenesis in seizure models.
Key references
Human clinical data are limited and largely negative or mixed. Japanese Phase II/III trials in dementia/cognitive sequelae after cerebrovascular disorders showed improvement over placebo in some early trials, but a Ministry of Health-mandated repeat Phase III trial under revised guidelines failed to demonstrate efficacy, and Daiichi Seiyaku withdrew its Japanese NDA (Translon) in February 2002. A US/Canada multicenter randomized double-blind Phase II trial (28 sites, 1999–2001, n=159) tested nefiracetam 600 mg and 900 mg/day vs. placebo for poststroke depression; the drug did not separate from placebo overall (response >70%, remission >40% in both arms) but showed significant benefit in the most-severely-depressed subgroup at 900 mg (Robinson et al., J Neuropsychiatry Clin Neurosci 2008). A related post hoc analysis examined apathy outcomes in the same cohort. Preclinical findings include: rat cortical neurons showed potentiation of native α4β2-type nicotinic acetylcholine receptor currents via a G(s)-protein-dependent pathway; rat dorsal root ganglion neurons showed dual concentration-dependent effects on GABA_A receptor-channel currents mediated via cAMP-dependent protein kinase and Gi/Go proteins; rat neuronal preparations showed enhancement of high-voltage-activated N/L-type Ca²⁺ channel currents and modulation of NMDA receptor function via PKC-dependent phosphorylation; rat passive avoidance models showed reversal of apomorphine-induced amnesia and preservation of hippocampal NCAM-mediated memory consolidation during scopolamine disruption.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and Nefiracetam are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dose Range
Route
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs